Samer Al Hadidi, M.D., recently joined the UAMS Myeloma Center in the Winthrop P. Rockefeller Cancer Institute and is treating patients with myeloma and other plasma cell disorders.
“I’m very happy to welcome Dr. Al Hadidi,” said Frits van Rhee, M.D., Ph.D., clinical director of the Myeloma Center upon Al Hadidi’s arrival. “I believe he is a strong addition to our team.”
Al Hadidi also serves as an assistant professor in the UAMS College of Medicine Department of Hematology and Oncology.
He completed his fellowship in hematology/oncology from Baylor College of Medicine in Houston, where he focused on cell and gene therapy. He completed his residency in internal medicine at Michigan State University in Flint, Michigan, and received a master’s degree in clinical research and statistical analysis from the University of Michigan in Ann Arbor.
Al Hadidi received his medical degree from School of Medicine, University of Jordan, in Amman, Jordan.
Pioneering researcher John D. Shaughnessy, Jr., Ph.D., has returned to the Myeloma Center as a principal staff scientist and professor of medicine.
Shaughnessy’s research is focused on developing new targeted therapies for multiple myeloma.
“Dr. Shaughnessy’s return to UAMS expands and strengthens our research and subsequent treatment here,” said Fenghuang (Frank) Zhan, M.D., Ph.D., director of research at the Myeloma Center. “He came to UAMS in 1996 specifically to create a tissue archive and accompanying genetic profiles on myeloma patients.”
The archive and profiles require long-term follow-up on uniformly treated patients to learn more about the genetics of short and long survival, Zhan added.
Shaughnessy received his doctorate degree in molecular biology from the University of Maryland and served his postdoctoral fellowship in the Mammalian Genetics Laboratory of the National Cancer institute’s Frederick Cancer Research and Development Center.